Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose

American Journal of Gastroenterology

Volumn 100, Issue 3, 2005, Pages 624-630

  Villanueva, Càndid ^a   Planella, Montserrat ^a   Aracil, Carles ^a   López Balaguer, Josep M ^a   González, Begoña ^a   Miñana, Josep ^a   Balanzó, Joaquim ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SOMATOSTATIN; TERLIPRESSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ESOPHAGUS VARICES BLEEDING; FEMALE; HEART OUTPUT; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HEPATIC VENOUS PRESSURE; HIGH RISK POPULATION; HUMAN; LIVER CIRRHOSIS; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VENOUS PRESSURE;

AGED; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HEART RATE; HEMODYNAMIC PHENOMENA; HUMANS; INFUSIONS, INTRAVENOUS; LIVER CIRCULATION; LIVER CIRRHOSIS; LYSINE VASOPRESSIN; MALE; MIDDLE AGED; SOMATOSTATIN; VASOCONSTRICTOR AGENTS; VENOUS PRESSURE;

EID: 16844366870     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40665.x     Document Type: Article

References (32)

1. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: An evidence-based approach. Semin Liver Dis 1999;19:475-505.
2. Villanueva C, Ortiz J, Sàbat M, et al. Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: A prospective randomized trial. Hepatology 1999;30:384-9.
3. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver. Comparison with vasopressin. Gastroenterology 1981;80:518-25.
4. Eriksson LS, Law DH, Wahren J. Influence of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis. Clin Physiol 1984;4:5-11.
5. Sonnenberg GE, Keller U, Perruchud A, et al. Effect of somatostatin on splanchnic haemodynamics in patients with cirrhosis of the liver and in normal subjects. Gastroenterology 1981;80:526-32.
6. Merkel C, Gatta A, Zuin R, et al. Effects of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis and portal hypertension. Digestion 1985;32:92-8.
7. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: A pathophysiologic approach to treatment. Semin Liver Dis 1986;6:318-31.
8. McCormick PA, Jenkins SA, McIntyre N, et al. Why portal hypertensive varices bleed and bleed: A hypothesis. Gut 1995;36:100-103.
9. Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis. A double-blind hemodynamic investigation. Hepatology 1995;22:106-11.
10. Abraldes JG, Bosch J. Somatostatin and analogues in portal hypertension. Hepatology 2002;35:1305-12.
11. Villanueva C, Ortiz J, Miñana J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001;121:110-7.
12. Sieber CC, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992;262(Suppl):G274-7.
13. Chatila R, Ferayorni L, Grupta TK, et al. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology 2000;31:572-6.
14. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 2001;120:975-83.
15. Merkel C, Gatta A, Bolognesi M, et al. Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 1988;33:1103-9.
16. Nevens F, Van Steenbergen W, Yap SH, et al. Assessment of variceal pressure by continuous non-invasive endoscopic registration: A placebo controlled evaluation of the effect of terlipressin and octreotide. Gut 1996;38:129-34.
17. Escorsell A, Bandi JC, Moitinho E, et al. Time profile of the hemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997;26:621-7.
18. Romero G, Kravetz D, Argonz J, et al. Terlipressin is more effective in decreasing variceal pressure than portal pressure in cirrhotic patients. J Hepatol 2000;32:419-25.
19. Møller S, Hansen EF, Becker U, et al. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20:51-9.
20. Kravetz D, Cummings SA, Groszmann RJ. Hyposensitivity to vasopressin in a hemorrhaged-transfused rat model of portal hypertension. Gastroenterology 1988;93:170-5.
21. Tsai YT, Lee FY, Lin HC, et al. Hyposensitivity to vasopressin in patients with hepatitis B-related cirrhosis during acute variceal hemorrhage. Hepatology 1991;13:407-12.
22. Moitinho E, Escorsell A, Bandi JC, et al. Somatostatin is less effective decreasing portal pressure during acute variceal bleeding than in stable conditions [Abstract]. J Hepatol 1998;28:74.
23. Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626-31.
24. Moitinho E, Planas R, Bañares R, et al. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001;35:712-8.
25. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001;120:161-9.
26. Nilsson G, Lindblom P, Ohlin M, et al. Pharmacokinetic of terlipressin after single iv doses to healthy volunteers. Drugs Exp Clin Res 1990;6:307-14.
27. Forsling ML, Aziz LA, Miller M, et al. Conversion of triglycyl- vasopressin to lysine-vasopressin in man. J Endocrinol 1980;85:237-44.
28. Blei AT. Vasopressin and analogs in portal hypertension. Different molecules but similar questions. Hepatology 1986;6:146-7.
29. Vosmik J, Jedlicka K, Mulder JL, et al. Action of the triglycyl hormonogen of vasopressin (glypressin) in patients with liver cirrhosis and bleeding esophageal varices. Gastroenterology 1977;72:605-9.
30. Lin HC, Tsai YT, Lee FY, et al. Systemic and portal haemodynamic changes following triglycyl-lysin-vasopressin plus nitroglycerin administration in patients with hepatitis B related cirrhosis. J Hepatol 1990;10:370-4.
31. Oberti F, Veal N, Kaassis M, et al. Hemodynamic effects of terlipressin and octreotide administration alone or in combination in portal hypertensive rats. J Hepatol 1998;29:103-11.
32. Moreau R, Cailmail S, Valla D, et al. Haemodynamic responses to a combination of terlipressin and octreotide in portal hypertensive rats. Aliment Pharmacol Ther 1997;11:993-7.